AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing ...

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...

Last year, the stock declined 62.6%, significantly underperforming the S&P 500 Index’s ($SPX) gain of 25%. Moderna reported its fourth quarter and full fiscal 2024 results last week. So far this year, ...

HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. (06660), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory ...

The scale of the problem has led analysts to predict that the market for RSV vaccines could eventually be worth several billion dollars a year. In trials, GSK’s vaccine significantly reduced the ...

caused by RSV through day 150 in healthy pre-term and full-term infants compared to placebo. The company plans to file the data with global regulatory authorities, setting up a possible market ...

We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at ...